In recent years, a substantial number of BET inhibitors have been identified, encompassing pan-inhibitors, BD1/BD2 selective inhibitors, dual inhibitors of kinases and BET, and PROTACs-based inhibitors.60,473,474 From a therapeutic standpoint, BET inhibitors are primarily developed for treating tumors, with some also showing potential in non-tumor diseases, such as VYN-201 and VYN-202, among other BD2 selective inhibitors.475. Here, DNER is linked to neoplasm.